Notice of Proposed Sale · 144
MapLight Therapeutics, Inc.
MPLTNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- MapLight Therapeutics, Inc.
- Issuer CIK
- 0001770069
- SEC file number
- 001-42914
- Phone
- 617-984-6300
- Person for whose account securities are to be sold
- Foff Erin Pennock
- Relationships to issuer
- Officer
- Street
- 800 CHESAPEAKE DRIVE
- City
- REDWOOD CITY
- State / country code
- CA
- Postal code
- 94063
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 48,158 | 1,825,669.78 | 42,620,000 | 07/15/2026 | NASDAQ | Jefferies LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Jefferies LLC
- Street
- 520 Madison Avenue, 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10022
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/30/2023 | Restricted Stock Unit Grant | Maplight Therapeutics, Inc. | 3,349 | N | 07/30/2023 | N/A |
| Common | 07/18/2025 | Restricted Stock Unit Grant | Maplight Therapeutics, Inc. | 60,346 | N | 07/18/2025 | N/A |
| Common | 05/02/2024 | Restricted Stock Unit Grant | Maplight Therapeutics, Inc. | 6,351 | N | 05/02/2024 | N/A |
| Common | 11/09/2023 | Restricted Stock Unit Grant | Maplight Therapeutics, Inc. | 1,546 | N | 11/09/2023 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Erin Pennock Foff | Common | 05/07/2026 | 4,438 | 126,629.81 |
| Erin Pennock Foff | Common | 05/06/2026 | 24,052 | 691,814.17 |
| Erin Pennock Foff | Common | 05/05/2026 | 10,576 | 298,207.77 |
| Erin Pennock Foff | Common | 05/04/2026 | 15,652 | 437,576.39 |
| Erin Pennock Foff | Common | 04/16/2026 | 1,169 | 31,997.52 |
| Erin Pennock Foff | Common | 04/15/2026 | 2,044 | 54,869.99 |
Seller — prior-sale row 1, entry 1
- Name
- Erin Pennock Foff
- Street
- 800 Chesapeake Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Seller — prior-sale row 2, entry 1
- Name
- Erin Pennock Foff
- Street
- 800 Chesapeake Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Seller — prior-sale row 3, entry 1
- Name
- Erin Pennock Foff
- Street
- 800 Chesapeake Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Seller — prior-sale row 4, entry 1
- Name
- Erin Pennock Foff
- Street
- 800 Chesapeake Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Seller — prior-sale row 5, entry 1
- Name
- Erin Pennock Foff
- Street
- 800 Chesapeake Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Seller — prior-sale row 6, entry 1
- Name
- Erin Pennock Foff
- Street
- 800 Chesapeake Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
1) A portion of the shares being sold is pursuant to a Rule 10b5-1 Trading Plan adopted on December 29, 2025. All representations regarding the absence of material non-public information were made at the time the plan was adopted. 2) The remaining shares to be sold is solely to satisfy tax withholding obligations arising from RSU vesting.
Notice signature
- Notice date
- 07/15/2026
- Signed
- Erin Foff
- Plan adoption dates
- 12/29/2025
Company context
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers.